| Company Name: |
BOC Sciences |
| Tel: |
1-631-485-4226; 16314854226 |
| Email: |
info@bocsci.com |
GCN2iB manufacturers
- GCN2iB
-
- $77.00
-
2026-08-20
- CAS:2183470-12-2
- Purity: 99.53%
- Supply Ability: 10g
- GCN2iB
-
- $77.00
-
2026-07-27
- CAS:2183470-12-2
- Purity: 99.53%
- Supply Ability: 10g
- GCN2iB
-
-
2026-07-22
- CAS:2183470-12-2
- Min. Order: 1KG
- Purity: 98%
- Supply Ability: 1000kg
|
| Product Name: | GCN2iB | | Synonyms: | GCN2iB;GCN2iB HCl salt;N-[3-[2-(2-Amino-5-pyrimidinyl)ethynyl]-2,4-difluorophenyl]-5-chloro-2-methoxy-3-pyridinesulfonamide;3-Pyridinesulfonamide, N-[3-[2-(2-amino-5-pyrimidinyl)ethynyl]-2,4-difluorophenyl]-5-chloro-2-methoxy-;inhibit,GCN-2iB,Inhibitor,GCN2iB,Eukaryotic Initiation Factor (eIF),Autophagy;N-(3-((2-Aminopyrimidin-5-yl)ethynyl)-2,4-difluorophenyl)-5-chloro-2-methoxypyridine-3-sulfonamide;N-(3-((2-Aminopyrimidin-5-yl)ethynyl)-2,4-difluorophenyl)-5-chloro-2-methoxypyridine-3-sulfonamide , GCN2iB;GCN2iB, 10 mM in DMSO | | CAS: | 2183470-12-2 | | MF: | C18H12ClF2N5O3S | | MW: | 451.83 | | EINECS: | | | Product Categories: | | | Mol File: | 2183470-12-2.mol |  |
| | GCN2iB Chemical Properties |
| Boiling point | 662.6±65.0 °C(Predicted) | | density | 1.63±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMSO : 16.67 mg/mL (36.89 mM);Water : < 0.1 mg/mL (insoluble) | | pka | 4.80±0.50(Predicted) | | form | Solid | | color | Off-white to light yellow | | InChI | InChI=1S/C18H12ClF2N5O3S/c1-29-17-15(6-11(19)9-23-17)30(27,28)26-14-5-4-13(20)12(16(14)21)3-2-10-7-24-18(22)25-8-10/h4-9,26H,1H3,(H2,22,24,25) | | InChIKey | JGHVXJKGYJYWOP-UHFFFAOYSA-N | | SMILES | C1(OC)=NC=C(Cl)C=C1S(NC1=CC=C(F)C(C#CC2=CN=C(N)N=C2)=C1F)(=O)=O |
| | GCN2iB Usage And Synthesis |
| Uses | N-[3-[2-(2-Amino-5-pyrimidinyl)ethynyl]-2,4-difluorophenyl]-5-chloro-2-methoxy-3-pyridinesulfonamide is an intermediate used in the preparation of heterocyclic compounds as GCN2 inhibitors. | | in vivo | In the antitumor activity study of the CCRF-CEM xenografts, ASNase or GCN2iB alone does not significantly affect tumor growth. Notably, a combination of ASNase and GCN2iB elicit potent antitumor activity (P=0.0002) with synergistic effects. In MV-4-11 and SU.86.86 xenografts, robust antitumor activity of the combination of GCN2iB and ASNase is observed with synergistic effect, respectively. ASNase/GCN2iB-treated tumors do not show significant growth even after drug cessation. The combination of ASNase and GCN2iB yield survival advantage compared with the vehicle treated control with synergistic effect[1]. | | IC 50 | eIF2 |
| | GCN2iB Preparation Products And Raw materials |
|